The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
Official Title: NON INTERVENTIONAL MULTICENTER STUDY, FOR THE VALIDATION OF MOLECULAR DIAGNOSTIC TECHNOLOGIES IN SUBJECTS WITH NON SMALL CELL LUNG CANCER (NSCLC) PROTOCOL N° X9001083
Study ID: NCT03220230
Brief Summary: This is a non-interventional multi-center with investigational sites in Chile and Brasil diagnostic study to validate novel diagnostic technologies, such as Next Generation Sequencing (NGS) from both tissue and blood compared to the current gold standard. As a non-interventional study, patients will receive the treatment indicated by their doctor independently of their participation on this study. Many cancer cells look the same under the microscope. But as these cells are studied at the molecular level, some genetic alterations or defects that are more common to certain types of cancer are identified. In some cases, these defects are what make the cells grow and multiply abnormally. Biomarkers are the molecular fingerprints of these genetic defects. By testing a sample of your tumor for biomarkers, doctors can learn if your cancer has one of these defects, and that may point to a specific treatment choice. One of the genetic biomarkers that are believed to cause some cancers to grow is the ALK fusion gene. About 3% to 5% of people with NSCLC may test positive for ALK. ROS1 is a receptor found in 1 to 2% of people with this type of cancer. The present study is designed to advance the molecular testing methodologies to identify ALK+ and ROS1+ NSCLC patients. A positive correlation with these new technologies will mean an efficient, more accurate diagnostic test, which could impact a greater number of cancer patients around world.
Detailed Description: B. Lung Cancer Non-small cell lung cancer (NSCLC) is a common cause of cancer mortality throughout the world. In 2007, there were 1.5 million new lung cancer cases diagnosed worldwide, including around 733,100 cases in the South American Region.6 Approximately 85% of lung cancer is histologically defined as non small cell and the remaining 14% as small cell. The majority of patients with NSCLC present with inoperable locally advanced (Stage IIIB) or metastatic (Stage IV) disease for which no curative treatment is yet available. In newly diagnosed patients with good performance status, platinum based doublet-combination chemotherapies are associated with a median overall survival (OS) of 7.4 to 9.9 months. 7, 8, 9, 10, 11, 12 Therefore, newer agents with novel mechanisms of action are still desperately needed for this serious life-threatening disease. 15,16 The rapid and efficient identification of key driver genes in non-small-cell lung cancer (NSCLC) is becoming increasingly important.17 Clinical screening efforts have revealed that the most common mutations in lung cancer specimens involve EGFR and KRAS, along with 10 other genes that show a prevalence of mutation in 5% or less of tumors. The ALK gene is rearranged in around 3%-5% of patients with NSCLC and has been the focus of intense basic and clinical research, suggesting that the frequency of the gene rearrangement is similar in Asian and Western patients. ROS1 is a receptor tyrosine kinase of the insulin receptor family. Chromosomal rearrangements involving the ROS1 gene were originally described in glioblastomas, where ROS1 (chromosome 6q22) is fused to the FIG gene (chromosome 6q22 immediately adjacent to ROS1), 16 and have been shown to be transforming in transgenic mice.17 More recently, ROS1 fusions were identified as potential driver mutations in an NSCLC cell line (HCC78; SLC34A2-ROS1) and an NSCLC patient sample (CD74-ROS1). 18 These fusions led to constitutive kinase activity and were associated with sensitivity in vitro and in vivo to crizotinib. As of December 2013, 16 different variants have been found.16, 17, 18 The present study is designed to advance the molecular testing methodologies to identify ALK+ and ROS1+ NSCLC patients. Advanced next generation sequencing screening methodologies will be used to identify NSCLC patients whose tumors contain a ROS1 gene inversion or translocation or an ALK translocation. A parallel test for ALK+ by either the Abbott ALK FISH test or the Ventana ALK IHC test is necessary to validate the NGS test in all samples. A parallel test for ROS1+ by either the Kreatech FISH test or the D4D6 ROS1 IHC test may be necessary to validate the NGS test in all samples.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centro Regional Integrado de Oncologia, Fortaleza, Caera, Brazil
Instituto Goiano de Oncología e Hematologia, Aparecida De Goiana, Goias, Brazil
Hospital Felicio Rocho, Belo Horizonte /MG, MG, Brazil
Hospital Luxemburgo, Belo Horizonte, MG, Brazil
Instituto de Cancer de Londrina, Londrina, Parana, Brazil
Centro de Pesquisa da Universidade Federal de Sao Paulo - UNIFESP, Sao Paulo, VILA Clementino, Brazil
Fundaçao Pio XII, Hospital do Cancer de Barretos, Barretos, , Brazil
Liga Paranaense de Combate ao Cancer Hospital Erasto Gaetner, Curtiba-PR, , Brazil
Hospital Sao Lucas da PUCRS, Porto Alegre, , Brazil
Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita, Porto Alegre, , Brazil
Instituto de Medicina Integral Prof. Fernando Figueira - IMIP, Recife, , Brazil
Instituto COI de Pesquisa Educacao e Gestao, Rio de Janeiro, , Brazil
Hospital Da Bahia, Salvador, , Brazil
Hospital Santa Izabel, Salvador, , Brazil
Nucleo de Oncologia da Bahia, Salvador, , Brazil
Instituto de Oncologia de Sorocaba - ONCO Clinicas Especializadas SC Ltda, Sao Paulo, , Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Paulo, , Brazil
Hospital Israelita Albert Einstein, São Paulo/SP, , Brazil
A.C. Camargo Cancer Center, São Paulo, , Brazil
Instituto Clinico Oncologico del Sur (ICOS), Temuco, Ranco, Chile
Hospital Base de Puerto Montt, Puerto Montt, Region DE LOS Lagos, Chile
Hospital Base de Valdivia, Valdivia, Region DE LOS Lagos, Chile
Centro Internacional de Estudios Clinicos, Santiago, RM, Chile
Hospital Clinico Universidad de Chile, Seccion de Oncologia, Independencia, Santiago, RM, Chile
Hospital Base de Arica, Arica, , Chile
Hosp Regional de Concepcion, Concepcion, , Chile
Universidad Católica del Norte, Coquimbo, , Chile
Instituto Nacional Del Torax, Santiago, , Chile
Hospital Carlos Alberto Seguin Escobedo, Arequipa, , Peru
Hospital Nacional Hipolito Unanue, El Agustino, , Peru
Clinica San Felipe, Lima, , Peru
Hospital Central de la Fuerza Aerea Peruana, Lima, , Peru
Instituto Nacional de Enfermedales Neoplasicas (INEN), Lima, , Peru
Oncosalud, Lima, , Peru
Unidad de Investigacion de la Clinica Internacional - Sede San Borja, Lima, , Peru
Clínica Quirurgica Santa Maria, Lima, , Peru
Centro de Investigación Clínica Trujillo E.I.R.L., Trujillo, , Peru
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Name: Ricardo Armisen, MD, PhD
Affiliation: CEMP Pfizer Chile
Role: STUDY_CHAIR